Chen et al. showed that the ENO1 inhibitor HuL227 downregulates tumor growth, angiogenesis, and recruitment of CCR2+ inflammatory monocytes in the PC-3 subcutaneous xenograft model of prostate cancer [124]. The gene discussed is ENO1; the disease is Familial prostate cancer.